Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS: [Ac 225]-RTX-2358 in Relapsed or Refractory Sarcoma
NCT07156565Phase 1Recruiting
- Sponsor
- Ratio Therapeutics
- Start
- Nov 2025
- Primary completion
- Jan 2028
- Modality
- Radiopharmaceutical
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of 225Ac-RTX-2358 in soft tissue sarcoma (STS), sponsored by Ratio Therapeutics. Primary endpoints: Safety and Tolerability (TEAEs, DLTs, SAEs) at 48 weeks, Preliminary anti-tumor activity at 48 weeks and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
225Ac-RTX-2358
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT07156565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07156565.